Eva Pharma Launches Major Cancer Drug Manufacturing Facility in Egypt to Address Growing Oncology Burden
Key Insights
Eva Pharma has launched a new oncology and hematology division in Egypt with an annual production capacity of 22 million packages, built to EU-GMP standards to strengthen pharmaceutical self-sufficiency.
Egypt's oncology centers receive approximately 360,000 cancer cases annually, including 80,000 patients under universal health insurance, with treatment costs reaching nearly EGP 13 billion per year.
The facility currently offers seven cancer and immunotherapy drugs in the local market, with plans to introduce 11 additional treatments and expand exports to regional and international markets.
Egypt's Health Minister Khaled Abdel Ghaffar announced the launch of Eva Pharma's new oncology and hematology division, representing a significant advancement in the country's pharmaceutical manufacturing capabilities and national health security strategy. The facility, built to European Good Manufacturing Practice (EU-GMP) standards, addresses Egypt's substantial cancer treatment burden while positioning the nation as a regional pharmaceutical hub.
Addressing Egypt's Cancer Treatment Challenge
Egypt's healthcare system faces considerable oncological demands, with cancer treatment centers receiving an average of 360,000 cases annually. Of these, 80,000 patients are covered under the Universal Health Insurance System, generating treatment costs of nearly EGP 13 billion per year. The scale of the challenge is further illustrated by data showing that between 2017 and 2022, Egypt recorded 366,823 cancer cases and 95,275 related deaths.
Manufacturing Capacity and Product Portfolio
The new Eva Pharma for Oncology facility boasts an annual production capacity of 22 million packages, with seven cancer and immunotherapy drugs already available in the Egyptian market. The company has outlined plans to introduce 11 additional treatments while expanding production for both domestic use and international export to regional markets.
This development contributes to Egypt's broader pharmaceutical infrastructure, which currently includes 2,700 pharmaceutical production lines across 179 drug factories. The country also operates facilities for biologics production, medical supplies manufacturing, and veterinary products, with 187 medical supply manufacturers and four biological product plants.
Strategic Healthcare Vision
Minister Abdel Ghaffar emphasized that the facility launch aligns with Egypt's Vision 2030 for healthcare system enhancement, particularly focusing on targeted therapies and immunotherapies. The initiative represents part of ongoing efforts to expand cancer treatment centers, update treatment protocols, and train specialized medical teams.
Eva Pharma's contribution extends beyond oncology, having previously supported national health initiatives including local manufacturing of Hepatitis C drugs, COVID-19 (search) antiviral treatments, insulin, and immunological medicines. The company's track record demonstrates its role in Egypt's pharmaceutical self-sufficiency strategy.
Regional Hub Development
The Ministry of Health described the launch as integral to a broader plan to achieve drug security, encourage research and innovation, and establish Egypt as a regional hub for advanced pharmaceutical manufacturing in the Middle East and Africa. Investment-friendly policies, streamlined drug registration processes, and partnerships with both local and international pharmaceutical manufacturers support this positioning strategy.
The facility's EU-GMP compliance ensures that locally manufactured cancer treatments meet international quality standards, potentially facilitating future export opportunities while providing Egyptian patients with access to affordable, high-quality oncology medications.